[1]罗艳红,张 颖,郑春艳,等.沙利度胺预防宫颈癌放疗所致急性放射性肠炎的效果及对IL-6水平的影响[J].医学信息,2020,33(21):143-145.[doi:10.3969/j.issn.1006-1959.2020.21.044]
　LUO Yan-hong,ZHANG Ying,ZHENG Chun-yan,et al.The Effect of Thalidomide in Preventing Acute Radiation Enteritis Caused by Radiotherapy of Cervical Cancer and Its Effect on IL-6 Level[J].Medical Information,2020,33(21):143-145.[doi:10.3969/j.issn.1006-1959.2020.21.044]
点击复制

沙利度胺预防宫颈癌放疗所致急性放射性肠炎的效果及对IL-6水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年21期
页码:
143-145
栏目:
药物与临床
出版日期:
2020-11-01

文章信息/Info

Title:
The Effect of Thalidomide in Preventing Acute Radiation Enteritis Caused by Radiotherapy of Cervical Cancer and Its Effect on IL-6 Level
文章编号:
1006-1959（2020）21-0143-03
作者:
罗艳红; 张 颖; 郑春艳; 等
（南华大学附属邵阳医院血液肿瘤科，湖南 邵阳 422000）
Author(s):
LUO Yan-hong; ZHANG Ying; ZHENG Chun-yan; et al
(Department of Hematology and Oncology,Shaoyang Hospital,Nanhua University,Shaoyang 422000,Hunan,China)
关键词:
沙利度胺; 急性放射性肠炎; 宫颈癌; 放疗; IL-6
Keywords:
Thalidomide; Acute radiation enteritis; Cervical cancer; Radiotherapy; IL-6
分类号:
R737.33
DOI:
10.3969/j.issn.1006-1959.2020.21.044
文献标志码:
A
摘要:
目的 观察沙利度胺预防宫颈癌放疗所致急性放射性肠炎（ARP）的效果及对患者血清IL-6水平的影响。方法 选择2019年1月~2020年2月我院收治的局部晚期宫颈癌患者90例，随机分为试验组与对照组，各45例。两组均采用同步放化疗，试验组在对照组的基础上口服沙利度胺直至放疗结束，比较两组放疗期间ARP的发生率，放疗前后血清IL-6水平及不良反应发生情况。结果 试验组Ⅰ~Ⅱ级ARP发生率（24.44%）低于对照组（42.22%），差异有统计学意义（P＜0.05）；对照组中出现3例Ⅲ级ARP，试验组未发生Ⅲ级ARP；试验组肌酐增高发生率低于对照组，嗜睡发生率高于对照组，差异有统计学意义（P＜0.05）；放疗后两组血清IL-6水平均高于放疗前，且对照组高于试验组，差异有统计学意义（P＜0.05）。结论 沙利度胺可降低局部晚期宫颈癌放疗所致急性放射性肠炎患者血清IL-6水平，从而预防急性放射性肠炎发生，安全性良好。
Abstract:
Objective To observe the effect of thalidomide in preventing acute radiation enteritis (ARP) caused by radiotherapy of cervical cancer and its effect on patients’ serum IL-6 levels.Methods 90 patients with locally advanced cervical cancer admitted to our hospital from January 2019 to February 2020 were selected and randomly divided into experimental group and control group, with 45 cases in each group. Both groups were treated with concurrent chemotherapy and radiotherapy. The test group was given thalidomide until the end of radiotherapy on the basis of the control group. The incidence of ARP, serum IL-6 levels before and after radiotherapy and the occurrence of adverse reactions were compared between the two groups during radiotherapy.Results The incidence of grade Ⅰ-Ⅱ ARP in the experimental group (24.44%) was lower than that in the control group (42.22%), the difference was statistically significant (P＜0.05); there were 3 cases of grade Ⅲ ARP in the control group, and no grade Ⅲ ARP in the experimental group The incidence of increased creatinine in the test group was lower than that of the control group, and the incidence of lethargy was higher than that of the control group, the difference was statistically significant (P＜0.05); the serum IL-6 levels of the two groups after radiotherapy were higher than those before radiotherapy, and the control group was higher in the experimental group, the difference was statistically significant (P<0.05).Conclusion Thalidomide can reduce the level of serum IL-6 in patients with acute radiation enteritis caused by radiotherapy for locally advanced cervical cancer, thereby preventing the occurrence of acute radiation enteritis, with good safety.

参考文献/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[2]Gami B,Harrington K,Blake P,et al.How patients manage gastrointestinal symptoms after pelvic radiotherapy[J].Aliment Pharmacol Ther,2003(18):987-994.[3]马腾辉,秦启元,王怀明,等.中国放射性直肠炎诊治专家共识(2018版)[J].中华胃肠外科杂志,2018,21(12):1321-1336.[4]周琦,吴小华,刘继红,等.宫颈癌诊断与治疗指南[J].中国实用妇科与产科杂志,2018,34(6):613-622．[5]于娇,雷雨,靳荣辉,等.沙利度胺防治急性放射性直肠炎的临床观察[J].肿瘤防治研究,2017,44(5):351-355.[6]程奇乐,王年飞,孙彤,等.小剂量沙利度胺预防宫颈癌放疗所致急性放射性肠炎的临床观察[J].安徽医学,2018,39(9):1102-1105.[7]Amirshahrokhi K,Khalili A.Thalidomide ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in an experimental model[J].Inflammation,2015,38(2):476-484.[8]张希梅,王佩国,袁智勇,等.对放射性肠炎的认识及其可能的机制探讨[J].中华放射肿瘤学杂志,2017,26(9):1099-1102.[9]Ong YZ,Rachel GJ,Bowen JM,et al.Pro-inflam-matory cytokines play a key role in the development of radio-therapy induced gastrointestinal mucositis[J].Radiation Enteritis,2010(5):22.[10]Tracey KJ,Lane F,Hilkens CM,et al.Introduction of toleranceby TNF-treated dentriticcells[J].Lancet,1990,8648(1):1721-1728.[11]Eun SH,Lim SM,Jang SE,et al.Lactobacillus sakei K17,an inducer of IL-10 expression in antigen-presenting cells,attenuates TNBS-induced colitis in mice[J].Immunopharmacol Immunotoxicol,2016,38(6):447-454.[12]尹卫华,夏红梅,钱小军,等.沙利度胺对放射性肺损伤大鼠免疫功能的影响[J].广东医学,2017,38(6):842-845.

相似文献/References:

[1]李宇鑫,周 露,郭 旦,等.沙利度胺预防鼻咽癌放射性口腔粘膜炎的效果及对患者血清TNF-α的影响[J].医学信息,2021,34(01):149.[doi:10.3969/j.issn.1006-1959.2021.01.040]
　LI Yu-xin,ZHOU Lu,GUO Dan,et al.The Effect of Thalidomide in Preventing Radiation-induced Oral Mucositis of Nasopharyngeal Carcinoma and Its Influence on Patients’ Serum TNF-α[J].Medical Information,2021,34(21):149.[doi:10.3969/j.issn.1006-1959.2021.01.040]
[2]陈 雪,张海龙.沙利度胺联合白芍总苷胶囊治疗复发性口腔溃疡的疗效[J].医学信息,2021,34(02):155.[doi:10.3969/j.issn.1006-1959.2021.02.043]
　CHEN Xue,ZHANG Hai-long.Therapeutic Effect of Thalidomide Combined with Total Glucosides of Paeony Capsules in the Treatment of Recurrent Oral Ulcer[J].Medical Information,2021,34(21):155.[doi:10.3969/j.issn.1006-1959.2021.02.043]
[3]方 敏.硼替佐米联合地塞米松与沙利度胺对多发性骨髓瘤伴肾功能不全患者骨代谢调节因子、免疫及肾功能的影响[J].医学信息,2022,35(05):165.[doi:10.3969/j.issn.1006-1959.2022.05.044]
　FANG Min.Effects of Bortezomib Combined with Dexamethasone and Thalidomide on Bone Metabolic Regulatory Factors,Immunity and Renal Function in Multiple Myeloma Patients with Renal Insufficiency[J].Medical Information,2022,35(21):165.[doi:10.3969/j.issn.1006-1959.2022.05.044]

更新日期/Last Update: 1900-01-01